Coagulation activation and fluid retention associated with the use of black cohosh: A case study

Climacteric

Volumn 13, Issue 2, 2010, Pages 187-191

  Zimmermann, R ^a   Witte, A ^b   Voll, R E ^c   Strobel, J ^a   Frieser, M ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Department of Internal Medicine 5 Hematology and Oncology ^*  (United States)

^c Nikolaus Fiebiger Center of Molecular Medicine   (United States)

Author keywords

Actaea racemosa; Autoimmune hepatitis; Black cohosh; Cimicifuga; Coagulation activation; Complementary and alternative medications; Phytoestrogens; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 5 LEIDEN; CIMICIFUGA RACEMOSA EXTRACT; COMFREY EXTRACT; D DIMER; HEPATITIS A VACCINE; HEPATITIS B VACCINE; KYTTA BALSAM; PARACETAMOL; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BLOOD CLOTTING; CASE REPORT; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEADACHE; HEMANGIOMA; HEPATITIS A; HEPATITIS B; HERBAL MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG EDEMA; MENOPAUSAL SYNDROME; MYASTHENIA GRAVIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THYMECTOMY; WATER RETENTION; WEIGHT GAIN;

ADULT; BLOOD COAGULATION; CIMICIFUGA; EDEMA; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; PHYTOTHERAPY; PLANT EXTRACTS; PREMENSTRUAL SYNDROME;

EID: 77249143964     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130902939921     Document Type: Article

References (28)

1. Amato P, Marcus DM. Review of alternative therapies for treatment of menopausal symptoms. Climacteric 2003;6:278-284
2. Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause 2007;14:541-549
3. Low Dog T. The role of complementary and alternative medicine during the menopausal transition. Menopause 2007;14:347-349
4. Bair YA, Gold EB, Zhang G, et al. Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation. Menopause 2008;15:32-43
5. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: A systematic review of its efficacy. Pharmacol Res 2008;58:8-14
6. Albertazzi P. Non-estrogenic approaches for the treatment of climacteric symptoms. Climacteric 2007;10(Suppl 2):115-120
7. Wuttke W, Gorkow C, Seidlová-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: A double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause 2006;13:185-196
8. Hirschberg AL, Edlund M, Svane G, Azavedo E, Skoog L, von Schoultz B. An isopropanolic extract of black cohosh does not increase mammographic breast density or breast cell proliferation in postmenopausal women. Menopause 2007;14:89-96
9. Reed SD, Newton KM, LaCroix AZ, Grothaus LC, Grieco VS, Ehrlich K. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study. Menopause 2008;15:51-58
10. Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 2003;51:5661-5670
11. Reame NE, Lukacs JL, Padmanabhan V, Eyvazzadeh AD, Smith YR, Zubieta JK. Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging. Menopause 2008;15:832-840
12. Mello NK. Commentary on black cohosh for the treatment of menopausal symptoms. Menopause 2008;15:819-820
13. Richardson MK. Black cohosh . . . a cautionary tale! Menopause 2008;15:583
14. Antoine C, Liebens F, Carly B, Pastijn A, Rozenberg S. Safety of alternative treatments for menopausal symptoms after breast cancer: A qualitative systematic review. Climacteric 2007;10:23-26
15. Joy D, Joy J, Duane P. Black cohosh: A cause of abnormal postmenopausal liver function tests. Climacteric 2008;11:84-88
16. Nisbet BC, O'Connor RE. Black cohosh-induced hepatitis. Del Med J 2007;79:441-444
17. European Medicines Agency on the Evaluation of Medicines for Human Use, Committee on herbal medicinal products (HMPC). Assessment of case reports connected to herbal medicinal products containing Cimicifugae racemosae rhizoma (black cohosh, root). Available at: http://www.emea.europa.eu/pdfs/ human/hmpc/ 26925806en.pdf
18. Mahady GB, Low Dog T, Barrett ML, et al. United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity. Menopause 2008;15:628-638
19. Cohen SM, O'Connor AM, Hart J, Merel NH, Te HS. Autoimmune hepatitis associated with the use of black cohosh: A case study. Menopause 2004;11:575-577
20. Singh B, Liu XD, Der-Martirosian C, et al. Menopausal issues: A national probability sample of US women. Altern Ther Health Med 2007;13:24-29
21. Blumenthal M, Cavaliere C, Ferrier G. Total sales of herbal supplements in United States show steady growth. HerbalGram 2006;71:64-66 Available at: http://content.herbalgram.org/ youngliving/herbalgram/articleview.asp?a=3012
22. Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): A systematic review of adverse events. Am J Obstet Gynecol 2008;199:455-466
23. Ingraffea A, Donohue K, Wilkel C, Falanga V. Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh. J Am Acad Dermatol 2007;56(5 Suppl):124-126
24. Frempong W, Kiuru A, Ericsson J, Farah M; the Uppsala Monitoring Centre. Cimicifuga racemosa L. Nutt. (Black cohosh) and anaphylactic reactions, including face and oral oedema. Available at: http://www.who-umc.org/graphics/ 6998.pdf
25. Minciullo PL, Saija A, Patafi M, Marotta G, Ferlazzo B, Gangemi S. Muscle damage induced by black cohosh (Cimicifuga racemosa). Phytomedicine 2006;13:115-118
26. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
27. Ohmoto K, Yamamoto S. Drug-induced liver injury associated with antinuclear antibodies. Scand J Gastroenterol 2002;37:1345-1346
28. Meliconi R, Perperas A, Jensen D, et al. Anti- LSP antibodies in acute liver disease. Gut 1982;23:603-607